Everything below concerns prothymosin alpha. We keep the language plain, cite what the science says, and separate well-supported claims from open questions.
Last reviewed on 2026-08-01. Where a claim depends on a specific study, the study is described rather than over-claimed.
The compound has been investigated as an adjunct in chronic viral hepatitis and as a vaccine adjuvant, with results that vary by study design and population. Regulators in some countries have approved a synthetic form for specific indications, while other agencies have not. Whether the peptide produces consistent clinical benefit across diverse patient groups is still an open question, and many trials have been small. Its status is therefore best described as investigational in many contexts and established only narrowly.
The name itself causes confusion, because several unrelated thymic peptides share the thymosin label. Thymosin beta-4, for example, is a different molecule with different functions. Naming conventions in the literature also mix descriptive research terms with assigned nonproprietary names, so a reader should confirm which entity a given paper addresses. Clarifying that point is usually the first step in interpreting any claim about this peptide.
Thymosin alpha-1 is a short peptide of 28 amino acid residues first described in the 1970s as a component of thymic extracts. Its N-terminal residue carries an acetyl group, and the sequence is highly conserved across mammalian species. The peptide is not encoded as a standalone gene product; it is released by proteolytic cleavage from the N-terminus of prothymosin alpha, a larger acidic nuclear protein. That precursor relationship places it within a broader family of thymic and immune-associated peptides that have been studied for decades.
Thymosin alpha 1 is approved as a medicine in several countries, including Italy and China, for indications such as chronic hepatitis B and as an immune adjuvant. It is not approved by the United States Food and Drug Administration as a therapeutic product. In research settings the peptide appears in studies of sepsis, vaccine response, and oncology support, often with mixed or inconclusive results. The evidence base is uneven, and reviews note that many trials were small. Regulatory status therefore differs widely between jurisdictions.
Thymosin alpha 1 is a synthetic 28-amino-acid peptide first isolated in 1966 from thymosin fraction 5, a bovine thymus extract. Its chain begins with an acetylated serine residue and ends with asparagine. The native peptide carries a molecular mass near 3,108 daltons. Researchers classify it as an immunomodulatory agent rather than a hormone with a single endocrine target. Early work framed it as a thymus-derived factor that supports T-cell maturation. The synthetic form used in research and clinical products matches the natural sequence.
Immune signaling studies link thymosin alpha 1 to Toll-like receptor pathways, particularly TLR2 and TLR9, on dendritic cells and other antigen-presenting cells. Activation of these receptors promotes maturation of T cells and increases natural killer cell activity. The peptide shifts cytokine output toward a T helper 1 profile, raising interferon gamma and interleukin 2 while modulating interleukin 10. Whether these effects translate into clinical benefit for any specific disease remains a subject of debate. Reported outcomes vary across trials and populations.
| Property | Value | Notes |
|---|---|---|
| Residue count | 28 amino acids | Acetyl group on the first residue |
| Approximate molecular mass | 3108 daltons | Calculated from the consensus sequence |
| Origin | Cleavage product of prothymosin alpha | Not encoded as a separate gene product |
| Primary research focus | Immune modulation | Studied in viral hepatitis and as a vaccine adjuvant |
| Common synonyms | Thymalfasin, Tα1, thymosin alpha 1 | Thymalfasin is the assigned nonproprietary name |
Quality control for thymosin alpha-1 focuses on identity, purity, and potency. Identity is confirmed by mass spectrometry and amino acid analysis, while purity is assessed by chromatography with limits on related substances and residual solvents. Potency assays may use cell-based immune readouts, but these are not standardized across laboratories. Regulatory status differs by jurisdiction; no product is approved in the United States for clinical use, whereas some other countries register injectable forms for specific indications.
Quantifying thymosin alpha-1 in a sample usually relies on reverse-phase high-performance liquid chromatography. The peptide lacks strong chromophores, so detection often occurs at 214 nm, where the peptide backbone absorbs. Mass spectrometry provides confirmatory identification and can detect sequence variants or truncations. Immunoassays have been used in biological matrices, but they may cross-react with related fragments. For purity assessment, chromatographic peak area gives the main component percentage, while mass accuracy verifies molecular identity.
Early work on thymic extracts in the 1960s described a heat-stable acidic fraction containing many polypeptides. Separation of that mixture yielded individual components, and thymosin alpha-1 was named as one of them on the basis of assays for T-cell activity. The first preparations came from calf thymus, while subsequent research and clinical material has been chemically synthesized. Nomenclature in older papers is inconsistent, and the same peptide sometimes appears under different designations, which complicates literature searches.
Most published studies on thymosin alpha-1 report changes in immune measurements rather than clinical outcomes, and findings differ across designs and populations. Whether the peptide signals through one defined receptor or through several less specific interactions remains an open question. Its reported circulation half-life of a few hours complicates comparison of dosing schedules across trials. Mechanistic claims are frequently drawn from isolated cell cultures, and how far those results extend to whole organisms is unresolved.
Thymosin alpha-1 is a synthetic peptide of 28 amino acids whose sequence matches the amino-terminal region of prothymosin alpha. The chain is acetylated at its first residue and contains one disulfide bridge between two cysteine residues, which folds the molecule into a compact loop. Its molecular formula, C129H215N33O55, corresponds to a monoisotopic mass of roughly 3,106 daltons. Material used in laboratories is made by solid-phase synthesis rather than isolated from animal tissue.
胸腺素α1对免疫系统的影响涉及多种细胞类型。研究表明，它可促进未成熟T细胞向成熟T细胞分化，并增强T细胞对抗原刺激的增殖反应。树突状细胞在Tα1存在下表达更高水平的共刺激分子，从而更有效地呈递抗原。此外，自然杀伤细胞的活性也观察到上升。这些效应并非直接杀伤病原体，而是调节宿主免疫应答的强度与方向。
在信号层面，Tα1可能通过Toll样受体等模式识别受体发挥作用。部分实验显示，它能激活髓样分化因子88依赖的通路，进而促进核因子κB进入细胞核。这导致白细胞介素2、干扰素γ和白细胞介素12等细胞因子的转录增加。这些细胞因子偏向辅助性T细胞1型应答，有助于细胞免疫。然而，具体受体和结合位点尚未完全确定，不同实验模型的结果存在差异。
Some notable analogues of DFMDA include DFMDMA (F2-MDMA), EIDA, and IDA, among others. Other fluorinated MDxx derivatives, for instance derivatives of MDEA, BDB, and MBDB, have also been described. DFMDA was first described in the scientific literature by Daniel Trachsel and colleagues in 2006. He described its properties and effects in humans in 2012 and 2013.
Electromagnetic spectrum refers to the full range of all frequencies of electromagnetic radiation and also to the characteristic distribution of electromagnetic radiation emitted or absorbed by that particular object. Devices used to measure an electromagnetic spectrum are called spectrograph or spectrometer. The visible spectrum is the part of the electromagnetic spectrum that can be seen by the human eye. The wavelength of visible light ranges from 390 to 700 nm. The absorption spectrum of a chemical element or chemical compound is the spectrum of frequencies or wavelengths of incident radiation that are absorbed by the compound due to electron transitions from a lower to a higher energy state. The emission spectrum refers to the spectrum of radiation emitted by the compound due to electron transitions from a higher to a lower energy state. Light from many different sources contains various colors, each with its own brightness or intensity. A rainbow, or prism, sends these component colors in different directions, making them individually visible at different angles. A graph of the intensity plotted against the frequency (showing the brightness of each color) is the frequency spectrum of the light. When all the visible frequencies are present equally, the perceived color of the light is white, and the spectrum is a flat line. Therefore, flat-line spectra in general are often referred to as white, whether they represent light or another type of wave phenomenon (sound, for example, or vibration in a structure).
Alice in Chains has sold over 30 million certified records in the United States, released two number-one albums, had 23 top 40 singles, and has received eleven Grammy Award nominations. The band was ranked number 34 on VH1's 100 Greatest Artists of Hard Rock. Alice in Chains was named 15th greatest live band by Hit Parader, with Staley placing as 27th-greatest heavy metal vocalist of all time. The band's second album, Dirt, was named 5th-best album in the last two decades by Close-Up magazine in 2008. In October 2008, Guitar World ranked Cantrell's solo in "Man in the Box" at No. 77 on their list of "100 Greatest Guitar Solos". In August 2009, Alice in Chains won the Kerrang! Icon Award. In November 2011, Jar of Flies was ranked number four on Guitar World magazine's top ten list of guitar albums of 1994. It was also featured in Guitar World magazine's "Superunknown: 50 Iconic Albums That Defined 1994" list, and in May 2014, the EP was placed at number five on Loudwire's "10 Best Hard Rock Albums of 1994" list. In June 2017, Metal Injection ranked Alice in Chains at number 1 on their list of "10 Heaviest Grunge Bands". Ozzy Osbourne ranked Facelift among his list of "10 Favorite Metal Albums".
This dish first became popular in the Heian period of Japan, when water was most commonly poured over rice, but beginning in the Edo period, green tea (particularly bancha and sencha) became a popular substitute due to its aroma and mild umami flavor. It is said that the direct ancestor of today's chazuke is a method of eating that was adopted by servants (apprentices) who were employed by merchants at that time so that they could finish their meal very quickly during their work. At that time, the servants spent most of their day working, and their meal times were controlled by their superiors, so this form of eating naturally arose. Pickles were almost the only side dish that the apprentices were allowed to eat freely in the simple meals, and they were often piled up in huge bowls. Since there was still no technology to keep cooked rice warm as it is today, chazuke was a convenient way to enjoy cold rice and to finish a meal quickly.
and likewise for angles B, C, with equality in the first part if the triangle is isosceles and the apex angle is at least 60° and equality in the second part if and only if the triangle is isosceles with apex angle no greater than 60°. Further, any two angle measures A and B opposite sides a and b respectively are related according to
Sources: en.wikipedia.org
replication eye Also replication bubble. The eye-shaped structure that forms when a pair of replication forks, each growing away from the origin, separates the strands of the double helix during DNA replication.
Particles such as whole cells or cell debris, which would clog a packed bed column, readily pass through a fluidized bed. EBA can therefore be used on crude culture broths or slurries of broken cells, thereby bypassing initial clearing steps such as centrifugation and filtration, which is mandatory when packed beds are used. In older EBA column designs, the feed flow rate is kept low enough that the solid packing remains stratified and does not fluidize completely. Hence EBA can be modelled as frontal adsorption in a packed bed, rather than as a well-mixed, continuous-flow adsorber.
=== 5 July === One person was killed in a Russian airstrike in Donetsk Oblast. In Russia, the governor of Rostov Oblast claimed that ten drones were shot down, causing a fire in Rostov-on-Don. The governor of Krasnodar Krai claimed that a child was killed in a drone attack in Primorsko-Akhtarsk.
==== Protease-specific Arrays ==== A protease specific protein array based on immobilized antibodies designed to capture specific proteases from biological samples offers a step up in analysis of protein levels beyond transcript expression. Capture antibodies spotted to nitrocellulose membranes can bind proteases in complex mixtures which have been pre-incubated and bound by detection antibodies allowing for parallel analysis of relative protease levels. These arrays offer parallelization of protein levels over traditional western blot. Unfortunately, these assays fail to provide insight on enzymatic function for proteases and suffer similar drawbacks to western blots regarding reliable quantification.
=== Vaccination and information === Modern societies are facing the challenge of "rational" exemption, i.e. the family's decision to not vaccinate children as a consequence of a "rational" comparison between the perceived risk from infection and that from getting damages from the vaccine. In order to assess whether this behavior is really rational, i.e. if it can equally lead to the eradication of the disease, one may simply assume that the vaccination rate is an increasing function of the number of infectious subjects:
Sources: en.wikipedia.org
It is usually classified as an immunomodulatory peptide rather than a classical hormone. It derives from the larger protein prothymosin alpha and acts mainly on immune cells. The thymosin label covers a group of distinct peptides, so the naming can be misleading.
The two share a family name but have different sequences, sizes, and functions. Thymosin beta-4 is a 43-residue peptide associated with actin binding and cell migration. Thymosin alpha-1 is a 28-residue peptide linked mainly to immune signaling.
Thymalfasin is the assigned international nonproprietary name for the synthetic 28-residue peptide. Thymosin alpha-1 is the descriptive research name for the same molecule. Which term appears depends on the context and the regulatory document.
It is a chain of 28 amino acids, with an acetyl group attached to the first serine residue. The synthetic version replicates this sequence. Its molecular mass is about 3,108 daltons.